Structure via PubChem · Public domain (PubChem)
ticlopidine
Sign in to saveAlso known as 4-C-32, 53-32C, Ticlid®, Ticlopidina, Ticlopidinum
Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs
Chemical data
- Formula
- C14H14ClNS
- Molecular weight
- 263.8 g/mol
- IUPAC name
- 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
- SMILES
- C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
- InChIKey
- PHWBOXQYWZNQIN-UHFFFAOYSA-N
- XLogP
- 3.6
- Polar surface area
- 31.5 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Wikidata facts
- Mass
- 263.054
Show 6 more facts
- chemical formula
- C₁₄H₁₄ClNS
- canonical SMILES
- C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
- World Health Organisation international non-proprietary name
- ticlopidine
- defined daily dose
- 0.5
- isomeric SMILES
- c1ccc(c(c1)C[N@]2CCc3c(ccs3)C2)Cl
- Commons category
- Ticlopidine
via Wikidata · CC0
~7 min read
Article
15 sectionsContents
- Medical uses
- Stroke
- Heart disease
- Contraindications
- Adverse effects
- Hematological
- Pregnancy and lactation
- Interactions
- Mechanism of action
- Pharmacokinetics
- Chemical properties
- History
- Research
- References
- External links
Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.
It was patented in 1973 and approved for medical use in 1978.